BioCryst Pharmaceuticals, Inc. BCRX R2KR3KPHARMA

Q: What is the current share price of BioCryst Pharmaceuticals, Inc. (BCRX)?

As of 2026-09-07 16:24 PDT, BioCryst Pharmaceuticals, Inc. (BCRX) trades at $9.96 on NasdaqGS. Its 52-week range is $6.24 to $11.11.

Q: What is the market capitalisation of BCRX?

BioCryst Pharmaceuticals, Inc. (BCRX) has a market capitalisation of $2.55B on NasdaqGS.

Q: What is the P/E ratio of BCRX?

BCRX trades at a trailing price-to-earnings (P/E) ratio of -7.11. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -5.27.

Q: Is BCRX a good stock to buy?

This page provides a data-driven analysis of BioCryst Pharmaceuticals, Inc. (BCRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://www.biocryst.com

Company Profile ↓

$9.96

+16.76% 1Y

Mkt Cap$2.55B

P/E-7.11

P/B-5.27

52W High$11.11

52W Low$6.24

Book Value$-1.78

EPS (TTM)$-1.40

Company Overview

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 107.2%.

Steady Revenue Expansion

Revenue has grown at a 17.8% CAGR over the past five years.

Healthy Margins

Operating margin of 45.1% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $874.84M (+94.1% YoY); net profit $263.86M.
Trailing 12 Months Year-on-year growth — revenue +33.6%, earnings +1400.0%.
5-Year Trend Long-term compounding — revenue CAGR 17.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	17.84%
1 Year:	33.60%

Compounded Profit Growth

5 Years:	-
1 Year:	1,400.00%

Stock Price Performance

1 Year:	+16.76%
6 Months:	+17.45%
3 Months:	+18.43%
1 Month:	+7.10%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 76% of range

$6.24 $11.11

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.55 · Neutral

Price Performance

1M+7.10%

3M+18.43%

6M+17.45%

1Y+16.76%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Healthy ROCE of 107.2%.
Compounding revenue at 17.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-7.11

Industry PE

25.17

Forward P/E

10.06

PEG Ratio

9.39

Book Value

$-1.78

Price to Book

-5.27

P/S

2.55

EV/EBITDA

6.60

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

17.84%

Profit 5Y

Revenue (YoY)

33.60%

Earnings (YoY)

1,400.00%

Profitability & Returns

ROCE

107.20%

ROE

ROA

52.86%

Profit Margin

-40.90%

Op Margin

45.12%

Gross Margin

77.39%

EPS (Latest Qtr)

$0.30

EPS (TTM)

$-1.40

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

2.22

Current Ratio

2.32

Debt

$836.64M

Total Assets

$557.85M

Current Assets

Working Capital

Ownership

Promoter Holding

1.20%

Chg in Prom Hold

-0.01%

FII / Inst Holding

105.28%

Chg in FII Hold

-0.07%

Financial Snapshot

Enterprise Value

$2.55B

Total Revenue (TTM)

$940.61M

EBITDA

$433.65M

Free Cash Flow

$324.27M

Operating Cash Flow

$376.14M

Shares Outstanding

255.54M

Gross Margin

77.39%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BCRX BioCryst Pharmaceuticals, Inc. R2KR3KPHARMA	9.96	-7.11	$2.55B	0.00%	107.20%	-	17.84%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026	Jun 2026
Revenue	25.84M	10.99M	-	4.82M	4.79M	7.76M	-	9.44M	3.10M	8.76M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	5.34M	-13.16M	-	-19.05M	-12.13M	-9.24M	-	-10.69M	-15.52M	-13.35M	-	-22.21M	-18.25M	-28.49M	-	-29.33M	-34.92M	-35.10M	-	-40.98M	-38.51M	-42.86M	-	-51.38M	-29.58M	-44.58M	-49.96M	-34.72M	-17.45M	-28.41M	-20.70M	-11.92M	-14.49M	8.76M	7.69M	21.23M	29.79M	29.59M	-701.60M	98.47M
Net Income	4.90M	-14.62M	-18.14M	-22.83M	-16.28M	-11.53M	-4.50M	-14.22M	-16.89M	-15.13M	-19.54M	-25.78M	-18.45M	-29.60M	-27.43M	-31.05M	-37.63M	-37.59M	-2.62M	-37.60M	-38.61M	-46.12M	-60.49M	-64.28M	-43.20M	-58.80M	-74.20M	-58.86M	-42.52M	-53.33M	-75.33M	-36.15M	-35.38M	-12.67M	-14.03M	32.00K	5.08M	12.90M	-721.81M	78.39M
Diluted EPS	0.06	-0.20	-0.25	-	-0.22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.24	-0.33	-0.40	-0.32	-0.23	-0.28	-0.40	-0.19	-0.17	-0.06	-0.07	0.00	0.02	0.06	-2.98	0.30
R&D Expense	16.52M	20.07M	-	20.58M	14.17M	14.11M	-	16.77M	15.76M	17.51M	-	18.44M	21.01M	22.01M	-	27.49M	27.68M	25.12M	-	29.87M	27.50M	30.25M	-	42.44M	52.87M	49.97M	65.36M	61.99M	52.74M	48.39M	51.25M	46.88M	46.49M	37.62M	41.08M	37.27M	43.39M	44.60M	60.32M	51.97M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	74.59M	62.38M	19.64M	26.29M	17.33M	13.61M	48.26M	26.35M	25.19M	20.65M	48.84M	17.81M	-	270.83M	331.41M	450.71M	874.84M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	6.59M	4.48M	12.27M	19.07M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	264.23M	326.93M	438.44M	855.76M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	412.67M	430.64M	440.99M	514.77M
Operating Income	-13.74M	-34.36M	-49.59M	-33.89M	-30.72M	-45.77M	-39.44M	-48.61M	-57.41M	-94.22M	-99.45M	-174.76M	-	-148.44M	-103.71M	-2.54M	340.99M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-143.85M	-116.33M	12.81M	347.65M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	99.09M	108.24M	98.52M	78.87M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-244.38M	-226.23M	-86.95M	267.39M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	2.73M	310.00K	1.93M	3.53M
Net Income	-13.45M	-33.85M	-56.95M	-39.08M	-30.11M	-45.19M	-43.02M	-55.14M	-65.78M	-101.25M	-108.90M	-182.81M	-	-247.12M	-226.54M	-88.88M	263.86M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-1.09	-	-1.33	-1.18	-0.43	1.21
R&D Expense	73.66M	83.90M	57.25M	49.16M	41.94M	51.80M	72.76M	61.01M	66.96M	84.89M	107.07M	122.96M	208.81M	253.30M	216.57M	174.64M	166.13M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	109.45M	82.21M	57.44M	48.87M	136.87M	122.36M	89.85M	178.26M	146.84M	175.28M	334.71M	588.15M	550.00M	516.96M	490.42M	514.16M
Total Equity	46.43M	86.27M	65.50M	14.81M	-454.00K	-1.13M	75.64M	47.72M	1.58M	83.77M	49.23M	38.25M	-19.26M	-106.99M	-294.60M	-455.53M	-475.93M	-119.15M
Cash & Equivalents	22.34M	41.12M	13.62M	16.44M	20.89M	21.16M	54.54M	28.90M	22.10M	50.28M	26.73M	114.17M	272.13M	504.39M	304.77M	110.64M	104.71M	89.74M
Long Term Debt	-	-	-	-	-	-	-	-	23.00M	23.00M	30.00M	0	119.73M	136.08M	231.62M	303.23M	314.87M	0
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	972.49M	966.35M	633.31M
Current Liabilities	-	-	28.00M	26.30M	17.22M	15.26M	57.29M	62.26M	54.36M	74.84M	69.48M	92.33M	105.65M	103.72M	105.51M	149.99M	160.38M	196.07M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-16.22M	-28.55M	-32.25M	-37.40M	-26.53M	-13.12M	-53.44M	-41.14M	-92.56M	-89.58M	-135.11M	-	-161.85M	-95.14M	-52.02M	347.37M
Investing Cash Flow	-12.89M	221.00K	11.32M	24.88M	-3.47M	-18.00M	23.27M	-64.64M	4.77M	77.93M	-6.86M	-	-128.24M	-131.50M	52.59M	-13.69M
Financing Cash Flow	47.90M	831.00K	23.75M	16.96M	30.27M	5.48M	23.30M	135.70M	62.50M	99.10M	300.59M	-	88.03M	32.48M	-5.76M	-349.93M
Capital Expenditure	-	-	-	-	-	-	-	-328.00K	-366.00K	-343.00K	-	-	-1.35M	-2.17M	-1.12M	-2.47M
Free Cash Flow	-	-	-	-	-	-	-	-41.47M	-92.93M	-89.93M	-	-	-163.20M	-97.31M	-53.14M	344.90M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-202.06M	-194.15M	-5.19M	-16.26M
Share Buybacks	155.00K	5.00K	61.00K	-	-	-	-	-	-	-	-	-	-	-	-	-

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	97.6%	98.6%	97.3%	97.8%
Operating Margin %	-18.4%	-55.1%	-252.4%	-128.9%	-177.2%	-336.4%	-81.7%	-184.4%	-227.9%	-456.2%	-203.7%	-981.1%	-	-54.8%	-31.3%	-0.6%	39.0%
Net Margin %	-18.0%	-54.3%	-289.9%	-148.6%	-173.7%	-332.1%	-89.1%	-209.3%	-261.2%	-490.3%	-223.0%	-1,026.4%	-	-91.2%	-68.4%	-19.7%	30.2%
ROE %	-15.6%	-51.7%	-384.6%	8,608.1%	2,673.9%	-59.7%	-90.1%	-3,494.6%	-78.5%	-205.7%	-284.7%	949.1%	-	83.9%	49.7%	18.7%	-221.4%
ROCE %	-	-42.2%	-88.7%	-84.3%	-91.4%	-57.5%	-65.6%	-137.0%	-55.5%	-121.8%	-119.9%	-76.3%	-	-33.4%	-28.3%	-0.8%	107.2%

Shareholding Pattern

Insiders

1.20%

Institutions

105.28%

Public Float

106.55%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.35%	23.89M	$234.63M
2	RA Capital Management, L.P.	6.19%	15.83M	$155.42M
3	State Street Corporation	5.94%	15.19M	$149.18M
4	Deerfield Management Company, L.P	5.91%	15.10M	$148.25M
5	Vanguard Capital Management LLC	4.45%	11.36M	$111.60M
6	Vanguard Portfolio Management LLC	4.36%	11.14M	$109.39M
7	TCG Crossover Management, LLC	4.31%	11.02M	$108.23M
8	Perceptive Advisors Llc	4.03%	10.31M	$101.23M
9	Jupiter Topco LLC	3.73%	9.54M	$93.69M
10	Vestal Point Capital, LP	3.25%	8.30M	$81.51M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BCRX

Google News Sun, 06 Sep 2026

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQMnNLcU1EV1FnemV1LWc1cm9YVm8zTlpSNXJIMzZ0U3VwdHZ6Uy1ZR3ZacTJZaEhiVUtCLTlDbDNlYm9XQjhxaEpBQlBCd1M5Z29sSUpTUHZEUGxxQmJicnBZVkxsMlE3dVh2SFhLRmFkRjdVMmxZUTQ0Zm1vTWJaZ2FTeGdBbWZ6blpOZD…

Google News hu, 13 Aug 2026

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOcFU0U3JxSDdKaHg4SFRqbWN5T29OYlQ1bFZFUWJPbnlXbVBfdDZEVnp0bHVOM2FLTnE0ZG5yTm1NY0dqQ2lrcnZXdW1nVzBnWld5VXMySEdXTDhCTy1FZ29KdnFNNmxNd05NTG5Ma2VJOWs4cGNwOEplemZ5OTFYT0ZoXy0wRW5PSk9td3…

Google News ue, 01 Sep 2026

Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPT3NRcmJOdGFSOXc1TmJsS1pidDk1d2diM1p4Tm13MjZiTjI1UF9kZ1hwekpteXYtNFl4UUZpUERzMVRoZEZ2bEtfWFl3dmtLOVhrNXVodkxuRlA0a0VRNE9tclVNR2ZCS3JQSk82NWhSVTd5ZjJRYmMxeVJNZlRyUDdlaGRiM3ZFeGkxeE…

Google News Wed, 05 Aug 2026

BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQTl90cjdHNGZUaE5PaEZBakhBaTVsZ3IxZTc3a203ZFp6cUZicEdDZnBuRFN6VUptU2JUdV9DOGlMT0V0WFpBaWNwQWRxMC1TUDlTeVFOX1RkWEJMVjBfTGtMcFliX0QtLXB1OVBoWHhubl8wWDNBdXlRcDE5TjJORHQ4UzRmbmt2alZSYV…

Google News Sun, 06 Sep 2026

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNUnEzQnJjVUdCZ21HelA2Q001SmtlMVZfTndDMkFCM3RxRlpWU1FRY2xJMU5PeDkzbHZ1azBlTnRjN21wV25DZjVJRmY2UWJTbXU4Y1dyUjRpWGFBei1WVFltU0VHM0MzU1ZsRk9vTXB1VFZqY1JobkZVMTBzSnBFaG1nekFRcVdxNWc1Nk…

Google News Sat, 29 Aug 2026

BCRX Should I Buy - Intellectia AI

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE90cjhWS044emNmaGU1Z0tmdWtIRkpBNDdtbmtCTU5wazZ5NnV6XzJrWXE4UGpyTXVlRUVuQ3A4SEhVQkd0cmpBSmVicjJQMUtaSk1LOGtHZW9EWWpPUHc?oc=5" target="_blank">BCRX Should I Buy</a>  <font c…

BCRX — Frequently Asked Questions

What is the current share price of BioCryst Pharmaceuticals, Inc. (BCRX)?

As of 2026-09-07 16:24 PDT, BioCryst Pharmaceuticals, Inc. (BCRX) trades at $9.96 on NasdaqGS. Its 52-week range is $6.24 to $11.11.

What is the market capitalisation of BCRX?

BioCryst Pharmaceuticals, Inc. (BCRX) has a market capitalisation of $2.55B on NasdaqGS.

What is the P/E ratio of BCRX?

BCRX trades at a trailing price-to-earnings (P/E) ratio of -7.11. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -5.27.

Is BCRX a good stock to buy?

This page provides a data-driven analysis of BioCryst Pharmaceuticals, Inc. (BCRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

BioCryst Pharmaceuticals, Inc. BCRX R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs? - Stocktwits

BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance

Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - Stock Titan

BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength - simplywall.st

BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits

BCRX Should I Buy - Intellectia AI

BCRX — Frequently Asked Questions

What is the current share price of BioCryst Pharmaceuticals, Inc. (BCRX)?

What is the market capitalisation of BCRX?

What is the P/E ratio of BCRX?

Is BCRX a good stock to buy?

Explore More